2021 was a transformational year for Shield Pharmaceuticals Plc and the specialty pharmaceutical company says it has got off to a solid start in 2022 with strong growth in revenue and demand.
Chief executive Greg Madison has been at the helm for twelve months which coincided with the company launching its lead product Feraccru®/Accrufer® in the US.
Madison talks to Proactive about expansion in the States, and what opportunities will be accelerated by June's financing agreement of US$10 million.